Pharmaceutical - Arena Pharmaceuticals

Filter

Current filters:

Arena Pharmaceuticals

Popular Filters

Arena Pharma in deal with Teva unit for marketing Belviq in Israel

Arena Pharma in deal with Teva unit for marketing Belviq in Israel

21-07-2014

USA-based Arena Pharmaceuticals has entered into an exclusive marketing and supply agreement for its…

AbicArena PharmaceuticalsBelviqLicensingMetabolicsObesityPharmaceuticalRegulationRest of the WorldTeva Pharmaceutical Industries

Eisai to further increase its Belviq sales force by 50%

Eisai to further increase its Belviq sales force by 50%

09-05-2014

USA-based Arena Pharmaceuticals says its marketing partner, Japan’s Eisai, plans to add more than 200…

Arena PharmaceuticalsBelviqEisaiManagementMetabolicsPharmaceuticalUSA

Report: Obesity therapy market forecast to reach $8.4 billion by 2022

Report: Obesity therapy market forecast to reach $8.4 billion by 2022

20-11-2013

Due to the launches of several novel drugs during the next decade, the obesity therapeutics market will…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNovo NordiskPharmaceuticalVictoza

Eisai to double Belviq sales force by December

Eisai to double Belviq sales force by December

15-10-2013

Eisai’s US subsidiary will increase its force for the obesity drug Belviq to around 400 representatives…

Arena PharmaceuticalsBelviqEisaiManagementMarkets & MarketingMetabolicsNorth AmericaPharmaceutical

Eisai's launch plan for obesity drug Belviq in USA enters consumer phase

16-09-2013

The US launch campaign by Japanese drug major Eisai (TYO: 4523) of the weight-loss drug Belviq (lorcaserin)…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceutical

Resubmission expected for Orexigen's obesity drug Contrave

29-08-2013

US biopharma company Orexigen Therapeutics (Nasdaq: OREX) has announced that the Light Study independent…

Arena PharmaceuticalsBelviqContraveGastro-intestinalsNorth AmericaOrexigen TherapeuticsPharmaceuticalQnexaRegulationVivus

It's official: "obesity is a disease," says AMA

20-06-2013

The American Medical Association at its annual meeting this week adopted a policy that recognizes obesity…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaRegulationVivus

Arena/Eisai's Belviq at last to launch in the USA

07-06-2013

USA-based Arena Pharmaceuticals (Nasdaq: ARNA) says that its long-awaited weight loss drug Belviq (lorcaserin)…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceutical

Arena and Eisai finally get DEA scheduling for obesity drug Belviq

08-05-2013

The long wait to get obesity drug Belviq (lorcaserin) to the US market, where it was approved by the…

Arena PharmaceuticalsBelviqEisaiMetabolicsNorth AmericaPharmaceuticalRegulation

Arena Pharma pulls EU application for Belviq; posts 1st-qtr results

06-05-2013

As part of an update on its activities and first-quarter financial results report, USA-based Arena Pharmaceutical…

Arena PharmaceuticalsBelviqEisaiEuropeFinancialMetabolicsPharmaceuticalRegulation

Arena Pharma licenses temanogrel to Ildong Pharma for South Korea

28-11-2012

The USA's Arena Pharmaceuticals (Nasdaq: ARNA) has entered into a co-development and license agreement…

Arena PharmaceuticalsAsia-PacificCardio-vascularIldong PharmaLicensingPharmaceuticalResearchtemanogrel

Arena Pharma links with Ildong for Belviq marketing in South Korea

08-11-2012

USA-based Arena Pharmaceuticals (Nasdaq: ARNA) has entered into a marketing and supply agreement with…

Arena PharmaceuticalsAsia-PacificBelviqIldong PharmaLicensingMarkets & MarketingMetabolicsPharmaceutical

Vivus' Qsymia set to be most widely used emerging therapy for obesity treatment

26-07-2012

Novel emerging agents will experience rapid uptake owing to the high prevalence of obese or overweight…

Arena PharmaceuticalsBelviqMarkets & MarketingMetabolicsPharmaceuticalQsymiaVivus

Arena Pharma files for Swiss approval of lorcaserin for weight control

12-07-2012

USA-based Arena Pharmaceuticals (Nasdaq: ARNA) this week filed with the Swiss health authority, Swissmedic,…

Arena PharmaceuticalsEuropelorcaserinMetabolicsPharmaceuticalRegulation

Eureka moment: US FDA approves first new obesity drug in 13 years

28-06-2012

After several years of investigation, and a rejection by the US regulator, the Food and Drug Administration…

Arena PharmaceuticalsBelviqEisailorcaserinMetabolicsNorth AmericaPharmaceuticalRegulation

Arena Pharma updates on lorcaserin filings in EU and USA

27-03-2012

San Diego, USA-based Arena Pharmaceuticals (Nasdaq: ARNA) revealed yesterday that the European Medicines…

Arena PharmaceuticalsEisaiEuropelorcaserinLorquessMetabolicsNorth AmericaPharmaceuticalRegulation

FDA updates on obesity drug candidates

11-01-2012

There have been two pieces of positive news coming out of the US Food and Drug Administration this week…

Arena PharmaceuticalsEisailorcaserinLorquessMetabolicsNorth AmericaPharmaceuticalQnexaRegulationVivus

Arena files complete response on lorcaserin

05-01-2012

In another attempt to gain approval for its obesity drug candidate that was turned down by US regulators…

Arena PharmaceuticalsEisailorcaserinLorquessMetabolicsNorth AmericaPharmaceuticalRegulationResearch

Obesity drug market set to grow to $2.6 billion by 2020, says DR report

27-09-2011

The obesity drug market will increase more than six-fold over the next decade, increasing from $420 million…

Arena PharmaceuticalsContraveLorqessMarkets & MarketingMetabolicsNovo NordiskOrexigen TherapeuticsPharmaceuticalQnexaVictozaVivus

Company Spotlight

ImmunoGen

ImmunoGen

Back to top